Parallel Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Parallel Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.33K	Sell	21 -4	-16%	-$362	﹤0.01%	3486
2026 Q1	$2.17K	Hold	25	–	–	﹤0.01%	3343
2025 Q4	$2.68K	Hold	25	–	–	﹤0.01%	3056
2025 Q3	$2.52K	Buy	25 +6	+32%	+$557	﹤0.01%	2992
2025 Q2	$1.2K	Hold	19	–	–	﹤0.01%	3164
2025 Q1	$1.01K	Hold	19	–	–	﹤0.01%	3127
2024 Q4	$1.06K	Hold	19	–	–	﹤0.01%	3101
2024 Q3	$995	Buy	19 +14	+280%	+$671	﹤0.01%	3037
2024 Q2	$205	Hold	5	–	–	﹤0.01%	3200
2024 Q1	$217	Hold	5	–	–	﹤0.01%	3140
2023 Q4	$230	Buy	+5	New	+$158	﹤0.01%	3153
2022 Q1	–	Sell	-50	Closed	–	–	3239
2021 Q4	$0	Sell	50 -131	-72%	-$1.47K	﹤0.01%	3268
2021 Q3	$2K	Buy	+181	New	+$2.76K	﹤0.01%	2720
2020 Q4	–	Sell	-90	Closed	-$2K	–	2696
2020 Q3	$2K	Hold	90	–	–	﹤0.01%	2337
2020 Q2	$2K	Buy	+90	New	+$1.75K	﹤0.01%	2231

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Parallel Advisors's RYTM Position: Q2 2026 in Review

Parallel Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 16% in Q2 2026, selling an estimated $362 and leaving 21 shares worth $2.33K. The position accounts for ﹤0.01% of the portfolio, ranked #3486.

Parallel Advisors first reported a position in RYTM in Q2 2020 and has held it in 15 quarters since. The position peaked at $2.68K in Q4 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Parallel Advisors held 21 shares of Rhythm Pharmaceuticals worth $2.33K as of Q2 2026.
Parallel Advisors sold 4 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $362.
Rhythm Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3486 holding.
Parallel Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
Parallel Advisors's Rhythm Pharmaceuticals position peaked at $2.68K in Q4 2025.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.